LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. In conne ...

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and ...

Revenue Performance - Revenue for Q3 2025 was $2.93 million, a slight decrease of 0.20% compared to $2.94 million in Q3 2024[5] - Revenues for the three months ended September 30, 2025, were $2,934 million, a slight decrease from $2,940 million in the same period of 2024[22] Profitability Metrics - Gross profit increased to $1.24 million in Q3 2025, up from $1.16 million in Q3 2024, resulting in a gross profit margin of 42.4% compared to 39.3% in the prior year[7][12] - Gross profit for the nine months ended September 30, 2025, was $3,690 million, compared to $1,674 million for the same period in 2024, indicating a significant increase[22] - Net loss attributable to NEXGEL stockholders narrowed to $0.65 million in Q3 2025 from a loss of $0.69 million in Q3 2024[9][12] - Net loss attributable to NexGel stockholders for the nine months ended September 30, 2025, was $2,030 million, an improvement from a net loss of $2,431 million in 2024[26] - Adjusted EBITDA remained stable at ($0.35) million for Q3 2025, consistent with Q3 2024[9][12] - Adjusted EBITDA for the nine months ended September 30, 2025, was $(1,275) million, compared to $(1,804) million in 2024, showing a reduction in losses[26] Cash and Assets - Cash balance as of September 30, 2025, was approximately $938 thousand, with an additional $920 thousand in restricted cash[10] - Cash and cash equivalents at the end of the period were $938 million, down from $1,059 million in 2024[24] - Total assets increased to $11.62 million as of September 30, 2025, compared to $10.98 million at the end of 2024[20] Expenses - Selling, general and administrative expenses increased slightly to $1.96 million in Q3 2025 from $1.94 million in Q3 2024, driven by higher compensation and consulting fees[8] - Total operating expenses for the nine months ended September 30, 2025, were $5,828 million, up from $4,387 million in 2024[22] - Research and development expenses for the three months ended September 30, 2025, were $7 million, compared to $0 in the same period of 2024[22] Operational Insights - The company reported stable revenue in contract manufacturing and branded products, indicating market confidence in its hydrogel technology[4] - The company is focused on expanding its innovative products across both contract manufacturing and consumer brands businesses[4] - NEXGEL has strategic partnerships with leading consumer healthcare companies, enhancing its market position[15] Cash Flow and Interest - The company reported a net cash used in operating activities of $1,592 million for the nine months ended September 30, 2025, an improvement from $3,008 million in 2024[24] - Interest expense, net for the nine months ended September 30, 2025, was $32 million, down from $65 million in 2024[26] Share Metrics - The weighted average shares used in computing net loss per common share - basic for the three months ended September 30, 2025, were 7,971,299, compared to 6,569,403 in 2024[22]

Revenue and Profit - For the three months ended September 30, 2025, revenues were $2,934, a decrease of $6 or 0.20% compared to $2,940 for the same period in 2024[187]. - Gross profit for the three months ended September 30, 2025 was $1,243, an increase of $88 from $1,155 in 2024, resulting in a gross profit margin of 42.4% compared to 39.2% in 2024[188]. - Revenues for the nine months ended September 30, 2025 were $8,625, an increase of $2,978 or 52.7% compared to $5,647 for the same period in 2024, driven by sales growth in branded consumer products[197]. - Gross profit for the nine months ended September 30, 2025 was $3,690, an increase of $2,016 from $1,674 in 2024, with a gross profit margin of approximately 42.8% compared to 29.6% in 2024[198]. Costs and Expenses - Total cost of revenues decreased by $94 or 5.2% to $1,691 for the three months ended September 30, 2025, primarily due to a decrease in depreciation and amortization expense[189]. - Cost of revenues increased by $962, or 24.2%, to $4,935 for the nine months ended September 30, 2025, compared to $3,973 for the same period in 2024[200]. - Selling, general, and administrative expenses rose by $1,511, or 35.1%, to $5,820 for the nine months ended September 30, 2025, from $4,309 in the prior year[201]. - Compensation and benefits increased by $167 or 69.9% to $406 for the three months ended September 30, 2025, reflecting an increase in the number of employees and officer compensation[191]. - Compensation and benefits increased by $406, or 54.6%, to $1,149 for the nine months ended September 30, 2025, compared to $743 for the same period in 2024[202]. - Research and development expenses were $7 for the three months ended September 30, 2025, compared to $0 in 2024, indicating an increase in investment in innovation[196]. - Research and development expenses decreased by $70, or 89.7%, to $8 for the nine months ended September 30, 2025, from $78 in the prior year[209]. - Share-based compensation rose by $57 or 39.8% to $200 for the three months ended September 30, 2025, due to the issuance of stock options and restricted awards[192]. - Advertising, marketing, and Amazon fees decreased by $170 or 20.7% to $650 for the three months ended September 30, 2025, as part of a strategy to optimize advertising spend[193]. - Professional and consulting fees increased by $45 or 12.0% to $420 for the three months ended September 30, 2025, due to ongoing public company governance requirements[195]. Cash Flow and Financial Position - Net cash used in operating activities was $1,592 for the nine months ended September 30, 2025, an improvement from $3,008 in the same period of 2024[212]. - Cash and cash equivalents at the end of the quarter were $1,858, compared to $1,059 at the end of September 30, 2024[212]. - Current assets totaled $5,602 and current liabilities totaled $3,308 as of September 30, 2025, resulting in working capital of $2,294[216]. Strategic Plans and Outlook - The company plans to explore new product channel sales in cosmetics, athletic products, and proprietary medical devices[218]. - The August Financing provided necessary working capital to continue strategic objectives, including the development of consumer products and proprietary medical devices[219]. - The company expects to continue incurring losses in the near term, with future operations dependent on managing and growing current products[220].

Financial Data and Key Metrics Changes - For Q3 2025, the company reported revenue of $2.9 million, flat year over year and slightly higher sequentially [4][12] - Gross profit margins improved year over year, coming in at 42.4% for Q3 2025, up from 39.3% in Q3 2024 [13][14] - Adjusted EBITDA loss narrowed to $354,000 in Q3 2025 from $419,000 in Q2 2025 and $500,000 in Q1 2025 [4][15] - Net loss attributable to stockholders was $653,000 for Q3 2025, compared to a net loss of $693,000 for Q3 2024 [15] Business Line Data and Key Metrics Changes - Contract manufacturing revenue totaled $907,000 for Q3 2025, showing a slight increase year over year and sequentially [5] - Consumer product segment revenue remained stable year over year and sequentially, despite some logistical delays affecting product launches [8] Market Data and Key Metrics Changes - The company anticipates a strong fourth quarter, driven by new product launches and holiday season sales [11][21] - The partnership with iRhythm is expected to contribute positively, with initial orders anticipated in Q4 [6][10] Company Strategy and Development Direction - The company is focused on expanding its contract manufacturing and consumer-branded product lines, with a robust pipeline of new customers [7][10] - A significant partnership with STADA has been established, with plans for multiple product launches in early 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential revenue growth in Q4, projecting full-year revenues between $12 million and $12.5 million [11][19] - The company is optimistic about narrowing its adjusted EBITDA loss further, potentially nearing break-even by year-end [11][30] Other Important Information - The company holds a cash balance of approximately $938,000 and a restricted cash balance of $920,000, related to non-dilutive financing from STADA [15] - The Institutional Review Board study on Hydrogels is complete, with publication expected before year-end [6] Q&A Session Summary Question: Can you elaborate on the logistical delays mentioned? - The delays were primarily due to customs issues, impacting product launches by approximately $100,000-$200,000 in potential sales [17][18] Question: What gives you confidence in the revised revenue guidance? - Confidence stems from ongoing growth in existing customer orders and anticipated strong performance in Q4, despite flat results in previous quarters [19][21] Question: What is the current order book like for contract manufacturing? - The order book is strong, with existing customers continuing to order and new customers expected to be onboarded soon [27] Question: Is the company still expecting to achieve positive EBITDA by year-end? - The company believes it can achieve positive EBITDA, depending on strong performance in consumer products during Q4 [30]

Core Viewpoint - NEXGEL, Inc. reported flat revenue year-over-year for Q3 2025, but showed improvement in Adjusted EBITDA loss, indicating operational efficiencies and growth in contract manufacturing and consumer branded products [3][4][8]. Financial Performance - Revenue for Q3 2025 was $2.93 million, a slight decrease of 0.20% from $2.94 million in Q3 2024 [4][10]. - Cost of revenues decreased to $1.69 million from $1.79 million in Q3 2024, attributed to lower material costs and reduced amortization and depreciation [5][10]. - Gross profit increased to $1.24 million, with a gross profit margin of 42.4%, up from 39.3% in Q3 2024 [6][10]. - Selling, general and administrative expenses rose slightly to $1.96 million from $1.94 million in Q3 2024, mainly due to increased compensation and consulting fees [7][10]. - Net loss attributable to NEXGEL stockholders was $0.65 million, an improvement from a net loss of $0.69 million in Q3 2024 [8][10]. Operational Highlights - The company experienced stable performance in contract manufacturing and branded products, with growth driven by partnerships and new customer onboarding [3][4]. - NEXGEL's consumer brands are gaining traction through new product launches in beauty and skincare [3]. Cash Position - As of September 30, 2025, NEXGEL had a cash balance of approximately $938 thousand and a restricted cash balance of $920 thousand, supported by $1 million in non-dilutive capital from STADA [9][10]. Shareholder Information - As of November 11, 2025, NEXGEL had 8,143,133 shares of common stock outstanding [9].

Core Viewpoint - NEXGEL, Inc. is set to report its financial results for the third quarter of 2025 on November 11, 2025, followed by a conference call to discuss the results [1]. Company Overview - NEXGEL is a prominent provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogel products for various applications [3]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [3]. - NEXGEL's product brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George, and it maintains strategic contract manufacturing relationships with leading consumer healthcare companies [3]. Financial Results Conference Call - The financial results conference call is scheduled for November 11, 2025, at 4:30 P.M. ET [2]. - Interested parties can join the live call via U.S. toll-free number 1-800-579-2543 or international number 1-785-424-1789 [2]. - A replay of the call will be available until November 25, 2025, using the U.S. toll-free number 1-844-512-2921 or international number 1-412-317-6671, with access code 11160116 [2]. An archived version of the webcast will be available for 90 days [2].

NEXGEL (NasdaqCM:NXGL) Conference Summary Company Overview - NEXGEL has transitioned into a consumer products company, generating approximately $8 million annually from direct-to-consumer products [1] - The company operates a 16,500 square foot facility in Langhorne, Pennsylvania, housing an electron beam accelerator, one of only two such facilities globally [2] Industry Position - NEXGEL produces hydrogels for both consumer and medical applications, with a focus on biocompatible products for sensitive skin [6] - The company has established a joint venture with CG, addressing bottlenecks in converting and packaging processes, which previously limited production capacity [4] Product Development and Innovations - NEXGEL is developing a drug delivery pipeline, including a diclofenac patch that delivers medication faster than traditional creams [7] - The company is exploring a patch for Apremilast delivery, targeting patients with stubborn lesions who cannot tolerate systemic treatments [9] - SilverSeal, a flagship product, is a 94% water wound dressing with antimicrobial properties, showing promise in reducing scarring [13] Strategic Partnerships - A significant partnership with Cintas Corporation involves distributing SilverSeal products, with strong reorder patterns observed [20][21] - NEXGEL has a joint venture with Stada, a major European consumer healthcare company, to market products in the U.S., with plans for multiple product launches [22][23] Financial Performance - The company reported over 100% revenue growth in Q2, driven by consumer product sales and contract manufacturing [34] - NEXGEL received $1 million in non-dilutive funding from Stada to support its joint venture and product launches [23][36] Future Outlook - The company anticipates significant revenue opportunities from partnerships, particularly with AbbVie regarding the Resonic cellulite treatment [26][28] - NEXGEL is actively pursuing additional partnerships and has a robust pipeline of research and development projects [29][36] Key Challenges - The medical device side of the business has longer lead times for revenue recognition compared to consumer products, which can delay financial performance [35] - The company is managing capacity issues and production bottlenecks as it scales operations [4][6] Additional Insights - NEXGEL's hydrogel technology is being explored for aesthetic applications, including laser hair removal, which could open new market opportunities [30][32] - The company is focused on maintaining a strong cash position to support ongoing marketing and product development initiatives [36]

Core Insights - NEXGEL, Inc. is set to present at the LD Micro Main Event XIX Conference on October 20, 2025, highlighting its position in the healthcare and consumer products market [1][2]. Company Overview - NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogel products for various applications [2]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [2]. - NEXGEL's product brands include SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George, indicating a diverse product portfolio [2]. Conference Details - The presentation will take place at 11:30 a.m. P.T. on October 20, 2025, at the Hotel Del Coronado in San Diego, California, specifically in Track 4 [2]. - A webcast of the presentation will be available, providing broader access to investors and stakeholders [2].

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was approximately $2.9 million, a 100% increase year over year and a slight sequential increase [5][17] - Gross margins improved to 43.6%, more than double the 20.3% reported in Q2 2024, and increased from 42.4% sequentially [5][18] - Adjusted EBITDA loss narrowed to negative $420,000 compared to negative $790,000 for the same period last year [6][20] - Net loss attributable to stockholders was $670,000, down from $890,000 in Q2 2024 [20] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased to $863,000, a 103% year over year increase from approximately $425,000 in 2024 [6] - Consumer products revenue increased by 95% year over year, driven by growth across the brand portfolio [12] Market Data and Key Metrics Changes - The company is seeing increased demand from domestic companies due to tariffs, although the impact on margins has been mild [35][36] - The partnership with Cintas remains strong, with ongoing sales of the SilverSeal product included in their wound care kits [7][75] Company Strategy and Development Direction - The company aims to continue expanding its contract manufacturing and white label business as a major driver of growth [11] - New product launches are planned, including an expanded beauty line and additional skincare solutions, reflecting the commitment to innovative, high-quality products [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive EBITDA by the end of the year and maintaining guidance for $13 million in revenue [15][81] - The company is preparing for potential economic downturns by focusing on high-margin consumer products and evaluating cost structures [66] Other Important Information - The company received $1 million in non-dilutive funding from STATA to support upcoming product launches and marketing initiatives [15][21] - The company has sufficient cash on hand, including recent capital raises, to support growth initiatives [21] Q&A Session Summary Question: Market opportunities for upcoming launches - Management discussed the potential for new digestive enzyme products, which target larger markets compared to existing products [22][23] Question: Retail strategy and brand consolidation - Management clarified that brands will maintain their unique identities and are currently exploring private label opportunities [25][27] Question: Manufacturing capacity and onboarding new customers - Current manufacturing capacity is underutilized, allowing for onboarding of new customers without immediate expansion [29][30] Question: Impact of tariffs on the business - Management noted a mild negative impact on margins but increased interest from domestic companies [35][36] Question: Status of AbbVie partnership - Management confirmed delays in the AbbVie project but remains optimistic about future developments [40][44] Question: New product details from Silly George - Management highlighted successful new product launches and strong sales performance [48][51] Question: Cash position and recession preparedness - Management is considering strategies for potential economic downturns while maintaining a focus on high-margin products [66] Question: Ranking of partnerships - Management identified key partnerships, including Cintas and AbbVie, as significant opportunities for growth [75]